ARTICLE | Product Development
Phase II data show Novo’s semaglutide leads the pack on NASH resolution
May 6, 2020 11:04 PM UTC
Novo Nordisk disclosed top-line Phase II data in NASH for semaglutide that puts the GLP-1 agonist in pole position with respect to mechanisms addressing NASH resolution.
The readout came as Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) announced strong growth in 1Q20 due to COVID-19-related stockpiling. ...
BCIQ Company Profiles